HemaChrom, a digital startup company measuring blood hemoglobin levels with smartphone technology, has won phase 1 of the National Institutes of Health’s RADx Tech for Maternal Health Challenge.
A digital health startup company known as HemaChrome recently won phase 1 of the National Institutes of Health’s (NIH) RADx Tech for Maternal Health Challenge.
Their winning smartphone technology is capable of measuring blood hemoglobin levels instantly and noninvasively. Young Kim, MD, founder and chief science officer of HemaChrome, developed the technology.
“Blood hemoglobin tests are among the most common laboratory tests because they are an indicator of a variety of diseases and disorders,” Kim said. “In fact, they are the most common laboratory tests conducted among obstetric patients. However, more than 2.2 million childbearing women in the U.S. have limited access to such testing.
According to Kim, invasive and expensive venous blood draws are often used to perform blood hemoglobin tests, needing high end equipment and trained professionals to complete the tests on-site. Using the app, blood hemoglobin tests will be available to everyone and easily accessible, with less barriers and a reduced cost.
A cash prize was rewarded to HemaChrome for winning phase 1 of the challenge. The technical and commercial viability of their product was tested by a panel of medical, scientific, and business experts. Now, they will receive in-house and in-kind support from the NIH which will speed the development, validation, and commercialization of the technology.
In the time leading to phase 2 of the challenge, biweekly meetings will occur between HemaChrome and NIH RADx experts.
“We are working with the NIH RADx team to identify and mitigate key risk factors for the accelerated development and implementation of our technology,” Kim said. “If we progress to the next phase, we will work with them to independently test and verify our technology’s performance and usability.
Kim’s research has been published in journals such as the November 2022 issue of Blood and the June 2020 issue of Optica, and he plans to write further papers and conduct future clinical studies.
Reference
Purdue-connected digital health startup wins phase 1 of NIH competition for maternal health. Purdue University. February 15, 2023. Accessed March 8, 2023. https://www.purdue.edu/newsroom/releases/2023/Q1/purdue-connected-digital-health-startup-wins-phase-1-of-nih-competition-for-maternal-health.html
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More